Angela Cox

Angela Cox

Auto-generated profile, based on publicly available information

Angela Cox

Sheffield Institute for Nucleic Acids (SInFoNiA), Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield , Sheffield

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2007 in Nature
Verified
Journal Article
Closed access
PDF file
DEDouglas F. Easton
Douglas F. Easton
KPKaren A. Pooley
Karen A. Pooley
ADAlison M. Dunning
Alison M. Dunning
PPPaul D. P. Pharoah
Paul D. P. Pharoah
DTDeborah Thompson
Deborah Thompson
BPBruce A. J. Ponder
Bruce A. J. Ponder

23 October 2017 in Nature
Verified
Journal Article
Open access
PDF file
KMKyriaki Michailidou
Kyriaki Michailidou
SLSara Lindström
Sara Lindström
JDJoe Dennis
Joe Dennis
JBJonathan Beesley
Jonathan Beesley
SHShirley Hui
Shirley Hui
DEDouglas F. Easton
Douglas F. Easton
Association analysis identifies 65 new breast cancer risk loci, predicts target genes for known risk loci and demonstrates a strong overlap with somatic driver genes in breast tumours. Genome-wide association studies for breast cancer have identified common genetic variation that influences susceptibility to this disease, but much of the genetic risk remains unexplained. Doug Easton and colleagues report a genome-wide association study for breast cancer in more than 122,000 cases and 105,000 controls. The authors genotyped a subset of these cases using OncoArray, a new, custom genome-wide single-nucleotide polymorphism (SNP) array for cancer genomics. Overall, they identify 65 loci newly associated with breast cancer susceptibility, and estimate that, together with 107 previously identified breast cancer susceptibility loci, these explain about 18 per cent of the familial relative risk of breast cancer. Polygenic risk scores may be used in risk prediction models and may improve early detection and targeted prevention of the disease. Breast cancer risk is influenced by rare coding variants in susceptibility genes, such as BRCA1, and many common, mostly non-coding variants. However, much of the genetic contribution to breast cancer risk remains unknown. Here we report the results of a genome-wide association study of breast cancer in 122,977 cases and 105,974 controls of European ancestry and 14,068 cases and 13,104 controls of East Asian ancestry1. We identified 65 new loci that are associated with overall breast cancer risk at P < 5 × 10−8. The majority of credible risk single-nucleotide polymorphisms in these loci fall in distal regulatory elements, and by integrating in silico data to predict target genes in breast cells at each locus, we demonstrate a strong overlap between candidate target genes and somatic driver genes in breast tumours. We also find that heritability of breast cancer due to all single-nucleotide polymorphisms in regulatory features was 2–5-fold enriched relative to the genome-wide average, with strong enrichment for particular transcription factor binding sites. These results provide further insight into genetic susceptibility to breast cancer and will improve the use of genetic risk scores for individualized screening and prevention.

1 January 2019 in The American Journal of Human Genetics
Verified
Journal Article
Open access
NMNasim Mavaddat
Nasim Mavaddat
KMKyriaki Michailidou
Kyriaki Michailidou
JDJoe Dennis
Joe Dennis
MLMichael Lush
Michael Lush
LFLaura Fachal
Laura Fachal
DEDouglas F. Easton
Douglas F. Easton
Stratification of women according to their risk of breast cancer based on polygenic risk scores (PRSs) could improve screening and prevention strategies. Our aim was to develop PRSs, optimized for prediction of estrogen receptor (ER)-specific disease, from the largest available genome-wide association dataset and to empirically validate the PRSs in prospective studies. The development dataset comprised 94,075 case subjects and 75,017 control subjects of European ancestry from 69 studies, divided into training and validation sets. Samples were genotyped using genome-wide arrays, and single-nucleotide polymorphisms (SNPs) were selected by stepwise regression or lasso penalized regression. The best performing PRSs were validated in an independent test set comprising 11,428 case subjects and 18,323 control subjects from 10 prospective studies and 190,040 women from UK Biobank (3,215 incident breast cancers). For the best PRSs (313 SNPs), the odds ratio for overall disease per 1 standard deviation in ten prospective studies was 1.61 (95%CI: 1.57-1.65) with area under receiver-operator curve (AUC) = 0.630 (95%CI: 0.628-0.651). The lifetime risk of overall breast cancer in the top centile of the PRSs was 32.6%. Compared with women in the middle quintile, those in the highest 1% of risk had 4.37- and 2.78-fold risks, and those in the lowest 1% of risk had 0.16- and 0.27-fold risks, of developing ER-positive and ER-negative disease, respectively. Goodness-of-fit tests indicated that this PRS was well calibrated and predicts disease risk accurately in the tails of the distribution. This PRS is a powerful and reliable predictor of breast cancer risk that may improve breast cancer prevention programs.

27 March 2013 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TCThe Breast and Ovarian Cancer Susceptibility Collaboration
The Breast and Ovarian Cancer Susceptibility Collaboration
KMKyriaki Michailidou
Kyriaki Michailidou
H(Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON)
Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON)
KIkConFab Investigators
kConFab Investigators
AGAustralian Ovarian Cancer Study Group
Australian Ovarian Cancer Study Group
DEDouglas F Easton
Douglas F Easton

25 May 2010 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
FBFiona M. Blows
Fiona M. Blows
KDKristy E. Driver
Kristy E. Driver
Marjanka SchmidtMarjanka Schmidt
Marjanka Schmidt
ABAnnegien Broeks
Annegien Broeks
FLFlora E. van Leeuwen
Flora E. van Leeuwen
DHDavid Huntsman
David Huntsman
Immunohistochemical markers are often used to classify breast cancer into subtypes that are biologically distinct and behave differently. The aim of this study was to estimate mortality for patients with the major subtypes of breast cancer as classified using five immunohistochemical markers, to investigate patterns of mortality over time, and to test for heterogeneity by subtype. We pooled data from more than 10,000 cases of invasive breast cancer from 12 studies that had collected information on hormone receptor status, human epidermal growth factor receptor-2 (HER2) status, and at least one basal marker (cytokeratin [CK]5/6 or epidermal growth factor receptor [EGFR]) together with survival time data. Tumours were classified as luminal and nonluminal tumours according to hormone receptor expression. These two groups were further subdivided according to expression of HER2, and finally, the luminal and nonluminal HER2-negative tumours were categorised according to expression of basal markers. Changes in mortality rates over time differed by subtype. In women with luminal HER2-negative subtypes, mortality rates were constant over time, whereas mortality rates associated with the luminal HER2-positive and nonluminal subtypes tended to peak within 5 y of diagnosis and then decline over time. In the first 5 y after diagnosis the nonluminal tumours were associated with a poorer prognosis, but over longer follow-up times the prognosis was poorer in the luminal subtypes, with the worst prognosis at 15 y being in the luminal HER2-positive tumours. Basal marker expression distinguished the HER2-negative luminal and nonluminal tumours into different subtypes. These patterns were independent of any systemic adjuvant therapy. The six subtypes of breast cancer defined by expression of five markers show distinct behaviours with important differences in short term and long term prognosis. Application of these markers in the clinical setting could have the potential to improve the targeting of adjuvant chemotherapy to those most likely to benefit. The different patterns of mortality over time also suggest important biological differences between the subtypes that may result in differences in response to specific therapies, and that stratification of breast cancers by clinically relevant subtypes in clinical trials is urgently required. Please see later in the article for the Editors' Summary

12 June 2017 in Nature Genetics
Verified
Journal Article
Open access
PDF file
SCSpiroMeta Consortium
SpiroMeta Consortium
JMJames D McKay
James D McKay
RHRayjean J Hung
Rayjean J Hung
YHYounghun Han
Younghun Han
XZXuchen Zong
Xuchen Zong
CAChristopher I Amos
Christopher I Amos
Christopher Amos and colleagues perform genome-wide association analysis for lung cancer using cohorts genotyped on the OncoArray and combing these with existing data. They identify 18 loci, 10 of which are new, finding heterogeneity across the different lung cancer subtypes, and explore candidate genes through eQTL analysis in lung tissue. Although several lung cancer susceptibility loci have been identified, much of the heritability for lung cancer remains unexplained. Here 14,803 cases and 12,262 controls of European descent were genotyped on the OncoArray and combined with existing data for an aggregated genome-wide association study (GWAS) analysis of lung cancer in 29,266 cases and 56,450 controls. We identified 18 susceptibility loci achieving genome-wide significance, including 10 new loci. The new loci highlight the striking heterogeneity in genetic susceptibility across the histological subtypes of lung cancer, with four loci associated with lung cancer overall and six loci associated with lung adenocarcinoma. Gene expression quantitative trait locus (eQTL) analysis in 1,425 normal lung tissue samples highlights RNASET2, SECISBP2L and NRG1 as candidate genes. Other loci include genes such as a cholinergic nicotinic receptor, CHRNA2, and the telomere-related genes OFBC1 and RTEL1. Further exploration of the target genes will continue to provide new insights into the etiology of lung cancer.